Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 4/20 | 0.64 |
| ▸ | PLOD3 | O60568 | 3/20 | 0.64 |
| ▸ | PLOD1 | Q02809 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664616 | 0.98 | PLOD2 (0.62) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL28972977 | 0.98 | PLOD2 (0.62) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL10948430 | 0.86 | PLOD2 (0.83) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL2003577 | 0.84 | KMT2A (0.52) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL200805 | 0.80 | PLOD2 (0.73) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL5160670 | 0.79 | PLOD2 (0.60) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL1919299 | 0.79 | PLOD2 (0.60) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL21276047 | 0.79 | PLOD2 (0.43) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL5163555 | 0.78 | CYP3A4 (0.64) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 | |
| SCHEMBL8053052 | 0.78 | PLOD2 (1.00) | PLOD2PLOD3PLOD1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240240077-A1 | COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND LIGHTING INCLUDING SAME, AND COMPOUND | TORAY INDUSTRIES, INC. (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-108203408-B | Pyrazole compound containing N-aryl sulfonate as well as synthesis and application thereof | 兰州大学 | 2020-07-21 | — | — | CN | disclosed |
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-08-20 | — | — | US | disclosed |
| EP-3083591-B1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| WO-2017076285-A1 | PREPARATION METHOD FOR TEDIZOLID, TEDIZOLID INTERMEDIATE, AND PREPARATION METHOD THEREFOR | 浙江华海药业股份有限公司 | 2017-05-11 | — | — | WO | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-5272036-A | Pattern forming contrast enhanced material utilizing water soluble photosensitive diazo compound and pattern forming method | MATSUSHITA ELECTRONIC INDUSTRIAL CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| EP-0210284-B1 | 1,3-DITHIOL-2-YLIDENE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4866182-A | TREATMENT OF HEART FAILURE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-12 | — | — | US | disclosed |
| EP-0329070-A1 | Cardiotonic alkanoyl and aroyl oxazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4668799-A | Anti-hepatitis and anti-cirrhotic 1,3-dithiol-2-ylidene derivatives, and pharmaceutical compositions therefor | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4650806-A | Cardiotonic 5-(heterylcarbonyl)-pyridones | STERLING DRUG INC. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0210284-A1 | 1,3-Dithiol-2-ylidene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0191298-A2 | 1,6 -Naphthyridin-2(1H) - ones useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4576943-A | NERVOUS SYSTEM DISORDERS, SEDATIVES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4567186-A | 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor | STERLING DRUG INC. (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385079-B2 | Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor | CYP51A1, CYP2F1, CYP4F11 | PLOD2 4536/4885PLOD3 4675/4885PLOD1 4019/4885 |
| US-20240240077-A1 | COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND LIGHTING INCLUDING SAME, AND COMPOUND | CDYL, ZKSCAN2, CAD | PLOD2 278/4885PLOD3 685/4885PLOD1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.